Intention to use a combined contraceptive method and decision after counselling in Switzerland Swiss data from the European CHOICE study

European Journal of Contraception and Reproductive Health Care

Volumn 17, Issue 2, 2012, Pages 119-127

  Merki Feld, Gabriele S ^a   Gruber, Isabel M L ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Merck Sharp and Dohme Chibret AG   (Switzerland)

Author keywords

Combined hormonal contraception; Combined oral contraceptive; Contraceptive counselling; Contraceptive patch; Vaginal ring

Indexed keywords

ADOLESCENT; ADULT; ADVERSE OUTCOME; ARTICLE; CONTRACEPTION; CONTRACEPTIVE COUNSELING; COUNSELING; DECISION MAKING; FEMALE; HUMAN; PILL; PRIORITY JOURNAL; RISK; SWITZERLAND; TRANSDERMAL PATCH; VAGINA RING;

ADOLESCENT; ADULT; CHOICE BEHAVIOR; CONTRACEPTION; COUNSELING; DECISION MAKING; FEMALE; HUMANS; SWITZERLAND;

EID: 84858396224     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625187.2011.630114     Document Type: Article

References (22)

1. Rosenberg MJ, Waugh MS, Long S. Unintended pregnancies and use, misuse and discontinuation of oral contraceptives. J Reprod Med 1995;40:355-60.
2. Hughey AB, Neustadt AB, Mistretta SQ, et al. Daily context matters: Predictors of missed oral contraceptive pills among college and graduate students. Am J Obstet Gynecol 2010;203:323, e321-7.
3. Smith JD, Oakley D. Why do women miss oral contraceptive pills? An analysis of women's self-described reasons for missed pills. J Midwifery Womens Health 2005; 50:380-5. (Pubitemid 41264363)
4. Oakley D, Yu M Y, Zhang YM, et al. Combining qualitative with quantitative approaches to study contraceptive pill use. J Womens Health 1999;8:249-57. (Pubitemid 29149850)
5. Ahrendt HJ, Nisand I, Bastianelli C, et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception 2006;74:451-7. (Pubitemid 46043314)
6. Merki-Feld GS, Hund M. Clinical experience with NuvaRing in daily practice in Switzerland: Cycle control and acceptability among women of all reproductive ages. Eur J Contracept Reprod Health Care 2007; 12:240-7. (Pubitemid 47347167)
7. Roumen F. Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaR-ing. Eur J Contracept Reprod Health Care 2002;7(Suppl. 2):19-24; discussion: 37-9. (Pubitemid 36269616)
8. Burkman RT. Transdermal hormonal contraception: Benefits and risks. Am J Obstet Gynecol 2007;197:134, e131-136.
9. Upson K, Reed SD, Prager S W, et al. Factors associated with contraceptive nonuse among US women ages 35-44 years at risk of unwanted pregnancy. Contraception 2010;81:427-4.
10. Tschudin S, Alder J, Merki GS, et al. Contraceptive counseling by gynecologists-which issues are discussed and does gender play a role? J Psychosom Obstet Gynae-col 2007;28:13-9.
11. Qin J P, Chen S, Di N, et al. Evaluation of the effect of post-abortion counseling and education among unmarried abortion adolescents. Zhonghua Fu Chan Ke Za Zhi 2010;45:201-4.
12. Halpern V, Grimes DA, Lopez L, et al. Strategies to improve adherence and acceptability of hormonal methods for contraception. Cochrane Database Syst Rev 2006:CD004317.
13. May WL, Johnson WD. A SAS(R) macro for constructing simultaneous confidence intervals for multinomial proportions. Comput Meth Prog Bio 1997;53:153-62. (Pubitemid 27305434)
14. Branden PS. Contraceptive choice and patient compliance. The health care provider's challenge. J Nurse Midwifery 1998;43:471-82. (Pubitemid 128724944)
15. Dehlendorf C, Diedrich J, Drey E, et al. Preferences for decision-making about contraception and general health care among reproductive age women at an abortion clinic. Patient Educ Couns 2010;81:343-8.
16. Weisman CS, Maccannon DS, Henderson JT, et al. Contraceptive counseling in managed care: Preventing unintended pregnancy in adults. Womens Health Issues 2002;12:79-95. (Pubitemid 34168526)
17. Dayal M, Barnhart KT. Noncontraceptive benefits and therapeutic uses of the oral contraceptive pill. Semin Reprod Med 2001;19:295-303. (Pubitemid 34028417)
18. Milsom I, Lete I, Bjertnaes A, et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. Hum Reprod 2006;21:2304-11. (Pubitemid 44530604)
19. Fisher WA, Black A. Contraception in canada: A review of method choices, characteristics, adherence and approaches to counselling. CMAJ 2007;176:953-61. (Pubitemid 46556839)
20. Spencer AL, Bonnema R, McNamara MC. Helping women choose appropriate hormonal contraception: update on risks, benefits, and indications. Am J Med 2009;122:497-506.
21. Duijkers I, Killick S, Bigrigg A, et al. A comparative study on the effects of a contraceptive vaginal ring NuvaRing and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function. Eur J Contracept Reprod Health Care 2004;9:131-40. (Pubitemid 39539574)
22. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: A prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998;179:577-82. (Pubitemid 28447229)